Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer - Concepedia

Concepedia

Publication | Closed Access

Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer

484

Citations

22

References

2006

Year

Nicholas J. Robert, Brian Leyland‐Jones, Lina Asmar, Robert J. Belt, D. Ilegbodu, David Loesch, Robert N. Raju, Elizabeth Valentine, Robert M. Sayre, Melody Cobleigh,

Journal of Clinical Oncology

Abstract

The addition of carboplatin to paclitaxel and trastuzumab improved ORR and PFS in women with HER-2-overexpressing MBC. This well-tolerated regimen represents a new therapeutic option.

References

	Year	Citations

Page 1